NCT02792114View on ClinicalTrials.gov

T-Cell Therapy for Advanced Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Breast CancerMetastatic HER2-negative Breast
Interventions
DRUG

Cyclophosphamide

BIOLOGICAL

Mesothelin-targeted T cells

DRUG

AP1903

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent and follow-up only), East White Plains

11553

Memorial Sloan Kettering Nassau (Consent and Follow-Up only), Uniondale

Unknown

Memorial Sloan Kettering Cancer Center (Consent and follow-up only), Basking Ridge

Memorial Sloan Kettering Cancer Center at Commack (Consent and follow-up only), Commack

07748

Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Memorial Sloan Kettering Cancer Center

OTHER